checkAd

     225  0 Kommentare Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti Meaningfully Reduces Utilization of Healthcare Resources - Seite 3

    The consistency of data on the GIMOTI experience amongst patients and providers including this DDW presentation is deeply important to inform the healthcare community and mirrors anecdotal descriptions of successful treatments we’ve received from physicians recently. We strongly believe GIMOTI has the potential to be the standard of care for DGP treatment,” commented Matt D’Onofrio, President and COO of Evoke Pharma.

    About Evoke Pharma, Inc.
    Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.

    Visit www.EvokePharma.com for more information.
    Follow GIMOTI on Facebook
    Follow Evoke Pharma on Facebook
    Follow Evoke Pharma on LinkedIn
    Follow Evoke Pharma on Twitter

    Lesen Sie auch

    About EVERSANA
    EVERSANA is a leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.

    Seite 3 von 6


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti Meaningfully Reduces Utilization of Healthcare Resources - Seite 3 Patients treated with Gimoti (metoclopramide) nasal spray showed statistically significant fewer emergency department visits, inpatient hospitalizations, and physician office visits than patients who were treated with oral metoclopramideSOLANA …

    Schreibe Deinen Kommentar

    Disclaimer